Equasens Société anonyme Beheer
Beheer criteriumcontroles 2/4
De CEO Equasens Société anonyme is Denis Supplisson, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. bezit rechtstreeks 0% van de aandelen van het bedrijf, ter waarde € 508.21. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 12.9 jaar.
Belangrijke informatie
Denis Supplisson
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 2.6yrs |
| Eigendom CEO | 0.00007% |
| Management gemiddelde ambtstermijn | 1.8yrs |
| Gemiddelde ambtstermijn bestuur | 12.9yrs |
Recente managementupdates
Recent updates
The Equasens Société anonyme (EPA:EQS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 03
Should You Think About Buying Equasens Société anonyme (EPA:EQS) Now?
Sep 28Equasens Société anonyme's (EPA:EQS) Intrinsic Value Is Potentially 75% Above Its Share Price
Jul 15Equasens Société anonyme's (EPA:EQS) Upcoming Dividend Will Be Larger Than Last Year's
Jun 22Is Equasens Société anonyme (EPA:EQS) Using Too Much Debt?
Jun 07Equasens Société anonyme (EPA:EQS) Is Aiming To Keep Up Its Impressive Returns
Apr 03At €51.10, Is It Time To Put Equasens Société anonyme (EPA:EQS) On Your Watch List?
Mar 08Some Confidence Is Lacking In Equasens Société anonyme's (EPA:EQS) P/E
Feb 14Estimating The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Jan 27Should You Investigate Equasens Société anonyme (EPA:EQS) At €59.70?
Nov 29These 4 Measures Indicate That Equasens Société anonyme (EPA:EQS) Is Using Debt Safely
Oct 28A Look At The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Sep 27Should You Think About Buying Equasens Société anonyme (EPA:EQS) Now?
Aug 05Equasens Société anonyme (EPA:EQS) Is Increasing Its Dividend To €1.15
Jun 11Equasens Société anonyme's (EPA:EQS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 22Equasens Société anonyme's (EPA:EQS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 08What Does Equasens Société anonyme's (EPA:EQS) Share Price Indicate?
Apr 04Equasens Société anonyme (EPA:EQS) Will Want To Turn Around Its Return Trends
Feb 13Calculating The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Jan 26At €71.60, Is Equasens Société anonyme (EPA:EQS) Worth Looking At Closely?
Dec 21Should You Be Adding Equasens Société anonyme (EPA:EQS) To Your Watchlist Today?
Dec 07Here's What's Concerning About Equasens Société anonyme's (EPA:EQS) Returns On Capital
Nov 12Is Equasens Société anonyme (EPA:EQS) Trading At A 26% Discount?
Oct 27Is Equasens Société anonyme (EPA:EQS) Using Too Much Debt?
Oct 12When Should You Buy Equasens Société anonyme (EPA:EQS)?
Sep 09With EPS Growth And More, Equasens Société anonyme (EPA:EQS) Makes An Interesting Case
Aug 24Equasens Société anonyme (EPA:EQS) Might Be Having Difficulty Using Its Capital Effectively
Jul 28Equasens Société anonyme (EPA:EQS) Is Increasing Its Dividend To €1.05
Jun 10Pharmagest Interactive (EPA:PHA) Has Announced That It Will Be Increasing Its Dividend To €1.05
May 27Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?
May 22Here's What Pharmagest Interactive's (EPA:PHA) Strong Returns On Capital Mean
Apr 25Are Investors Undervaluing Pharmagest Interactive SA (EPA:PHA) By 28%?
Feb 23Here's Why I Think Pharmagest Interactive (EPA:PHA) Might Deserve Your Attention Today
Feb 09Is Pharmagest Interactive SA (EPA:PHA) Potentially Undervalued?
Jan 25Many Would Be Envious Of Pharmagest Interactive's (EPA:PHA) Excellent Returns On Capital
Jan 06Pharmagest Interactive (EPA:PHA) Could Easily Take On More Debt
Nov 14Is There An Opportunity With Pharmagest Interactive SA's (EPA:PHA) 20% Undervaluation?
Oct 30Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?
Sep 28Is Pharmagest Interactive SA (EPA:PHA) Trading At A 20% Discount?
Jul 18Pharmagest Interactive (EPA:PHA) Will Want To Turn Around Its Return Trends
Jun 24Does Pharmagest Interactive (EPA:PHA) Deserve A Spot On Your Watchlist?
Apr 08Pharmagest Interactive SA (EPA:PHA) Is An Attractive Dividend Stock - Here's Why
Mar 24Pharmagest Interactive SA's (EPA:PHA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 03Our Take On The Returns On Capital At Pharmagest Interactive (EPA:PHA)
Feb 09
Shareholders of Pharmagest Interactive (EPA:PHA) Must Be Delighted With Their 500% Total Return
Jan 12What To Know Before Buying Pharmagest Interactive SA (EPA:PHA) For Its Dividend
Dec 15Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | €42m |
| Mar 31 2024 | n/a | n/a | €45m |
| Dec 31 2023 | n/a | n/a | €47m |
| Jun 30 2023 | n/a | n/a | €48m |
| Mar 31 2023 | n/a | n/a | €47m |
| Dec 31 2022 | €400k | €176k | €46m |
| Jun 30 2022 | n/a | n/a | €42m |
| Mar 31 2022 | n/a | n/a | €41m |
| Dec 31 2021 | €353k | €133k | €39m |
| Sep 30 2021 | n/a | n/a | €37m |
| Jun 30 2021 | n/a | n/a | €35m |
| Mar 31 2021 | n/a | n/a | €33m |
| Dec 31 2020 | €371k | €133k | €31m |
| Sep 30 2020 | n/a | n/a | €29m |
| Jun 30 2020 | n/a | n/a | €27m |
| Mar 31 2020 | n/a | n/a | €27m |
| Dec 31 2019 | €225k | €133k | €27m |
| Sep 30 2019 | n/a | n/a | €27m |
| Jun 30 2019 | n/a | n/a | €26m |
| Mar 31 2019 | n/a | n/a | €26m |
| Dec 31 2018 | €208k | €128k | €25m |
| Sep 30 2018 | n/a | n/a | €25m |
| Jun 30 2018 | n/a | n/a | €24m |
| Mar 31 2018 | n/a | n/a | €24m |
| Dec 31 2017 | €189k | €114k | €23m |
Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Denis redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de French markt.
Compensatie versus inkomsten: De vergoeding van Denis is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Denis Supplisson (55 yo)
2.6yrs
Tenure
€400,201
Compensatie
Mr. Denis Supplisson serves as Chief Executive Officer at Pharmagest Interactive SA since April 22, 2022. He served as Deputy Managing Director/Deputy Chief Executive Officer & Manager of the Europe Pharma...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder & Chairman of the Board | 14.8yrs | geen gegevens | 0.036% € 258.9k | |
| Deputy CEO | 4.3yrs | €428.66k | 0.000070% € 508.2 | |
| Chief Executive Officer & Director | 2.6yrs | €400.20k | 0.000070% € 508.2 | |
| Director | no data | €330.17k | 0.16% € 1.2m | |
| Group Chief Administrative & Financial Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Head of Communications | less than a year | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 5.1yrs | geen gegevens | geen gegevens | |
| Head of the Medical Solutions Division | less than a year | geen gegevens | geen gegevens | |
| Deputy MD & Head of the Pharmagest Division | less than a year | geen gegevens | geen gegevens |
1.8yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van EQS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder & Chairman of the Board | 14.8yrs | geen gegevens | 0.036% € 258.9k | |
| Deputy CEO | 4.3yrs | €428.66k | 0.000070% € 508.2 | |
| Chief Executive Officer & Director | 11.8yrs | €400.20k | 0.000070% € 508.2 | |
| Director | 15.4yrs | €330.17k | 0.16% € 1.2m | |
| Director | 22.5yrs | €6.91k | 0.0033% € 24.2k | |
| Director | 13.8yrs | geen gegevens | geen gegevens | |
| Director | 13.8yrs | €7.07k | 0.0027% € 20.0k | |
| Director | 13.4yrs | geen gegevens | 0.0046% € 33.3k | |
| Independent Director | 12.4yrs | €6.76k | 0.00017% € 1.2k | |
| Independent Director | 7.4yrs | €6.91k | 0.00013% € 943.8 | |
| Director | 7.4yrs | €604.00 | 0.00011% € 798.6 | |
| Independent Director | 1.4yrs | geen gegevens | 0.000010% € 72.6 |
12.9yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van EQS zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.9 jaar).